| 1901 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
64 |
| 1902 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
56 |
| 1903 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
Germany |
56 |
| 1904 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
64 |
| 1905 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
56 |
| 1906 |
Apheresis |
Autologous |
Follicular lymphoma |
Hematology |
2024 |
Standard Therapy |
Germany |
58 |
| 1907 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
65 |
| 1908 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
47 |
| 1909 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
69 |
| 1910 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
Germany |
38 |
| 1911 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
65 |
| 1912 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
70 |
| 1913 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
64 |
| 1914 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
53 |
| 1915 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
60 |
| 1916 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
59 |
| 1917 |
Apheresis |
Autologous |
Mantle cell lymphoma |
Hematology |
2024 |
Standard Therapy |
Germany |
45 |
| 1918 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
66 |
| 1919 |
Apheresis |
Autologous |
Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
Germany |
33 |
| 1920 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
64 |
| 1921 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
59 |
| 1922 |
Apheresis |
Allogeneic |
Primary myelofibrosis |
Hematology |
2024 |
Standard Therapy |
Germany |
55 |
| 1923 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
63 |
| 1924 |
Apheresis |
Allogeneic |
Blastic Plasmacytoid Dendritic |
Hematology |
2024 |
Standard Therapy |
USA |
57 |
| 1925 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
32 |
| 1926 |
Apheresis |
Allogeneic |
Macrofocal multiple myeloma |
Hematology |
2024 |
Standard Therapy |
USA |
75 |
| 1927 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
United Kingdom |
62 |
| 1928 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
52 |
| 1929 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
48 |
| 1930 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
United Kingdom |
71 |
| 1931 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Romania |
35 |
| 1932 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Lithuania |
47 |
| 1933 |
Apheresis |
Allogeneic |
Diffuse large B-cell lymphoma |
Hematology |
2024 |
Standard Therapy |
Australia |
46 |
| 1934 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
65 |
| 1935 |
Apheresis |
Allogeneic |
Chronic lymphatic leukemia |
Hematology |
2024 |
Standard Therapy |
Norway |
52 |
| 1936 |
Apheresis |
Allogeneic |
Chronic myelogenous leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
60 |
| 1937 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Hungary |
32 |
| 1938 |
Apheresis |
Allogeneic |
Malignant histiocytosis |
Hematology |
2024 |
Standard Therapy |
Bulgaria |
41 |
| 1939 |
Apheresis |
Allogeneic |
Myelodysplastic syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
78 |
| 1940 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Hungary |
20 |
| 1941 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
58 |
| 1942 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Portugal |
67 |
| 1943 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
63 |
| 1944 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Lithuania |
19 |
| 1945 |
Apheresis |
Allogeneic |
Hodgkin lymphoma |
Hematology |
2024 |
Standard Therapy |
Russia |
34 |
| 1946 |
Apheresis |
Allogeneic |
chronic lymphocytic leukemia Richters Transformation |
Hematology |
2024 |
Standard Therapy |
United Kingdom |
68 |
| 1947 |
Apheresis |
Allogeneic |
Myelodysplasia |
Hematology |
2024 |
Standard Therapy |
Sweden |
66 |
| 1948 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
52 |
| 1949 |
Apheresis |
Allogeneic |
Myelodysplasia |
Hematology |
2024 |
Standard Therapy |
Lithuania |
70 |
| 1950 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
72 |
| 1951 |
Apheresis |
Allogeneic |
plasma cell leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
59 |
| 1952 |
Apheresis |
Allogeneic |
Fibrolamellar Carcinoma |
Hematology |
2024 |
Standard Therapy |
Czechia |
41 |
| 1953 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
59 |
| 1954 |
Apheresis |
Allogeneic |
post-ET Myelofibrose |
Hematology |
2024 |
Standard Therapy |
Austria |
61 |
| 1955 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
55 |
| 1956 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2024 |
Standard Therapy |
Poland |
67 |
| 1957 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Spain |
45 |
| 1958 |
Apheresis |
Allogeneic |
Myelofibrose |
Hematology |
2024 |
Standard Therapy |
Spain |
69 |
| 1959 |
Apheresis |
Allogeneic |
Myelofibrose |
Hematology |
2024 |
Standard Therapy |
Poland |
60 |
| 1960 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
53 |
| 1961 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
France |
35 |
| 1962 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
69 |
| 1963 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Norway |
18 |
| 1964 |
Apheresis |
Allogeneic |
Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
51 |
| 1965 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
62 |
| 1966 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Hungary |
56 |
| 1967 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2024 |
Standard Therapy |
USA |
19 |
| 1968 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Spain |
67 |
| 1969 |
Apheresis |
Allogeneic |
Hemophagocytic Lymphohistiocytosis |
Hematology |
2024 |
Standard Therapy |
United Kingdom |
48 |
| 1970 |
Apheresis |
Allogeneic |
Non-Hodgkin's lymphoma |
Hematology |
2024 |
Standard Therapy |
NETHERLANDS |
61 |
| 1971 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
29 |
| 1972 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
62 |
| 1973 |
Apheresis |
Allogeneic |
Hodgkin Lymphoma |
Hematology |
2024 |
Standard Therapy |
Israel |
63 |
| 1974 |
Apheresis |
Allogeneic |
ETP-Acute Lymphoblastic Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
35 |
| 1975 |
Apheresis |
Allogeneic |
Hodgkin lymphoma |
Hematology |
2024 |
Standard Therapy |
Poland |
4 |
| 1976 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Germany |
23 |
| 1977 |
Apheresis |
Allogeneic |
Fanconi Anemia |
Hematology |
2024 |
Standard Therapy |
USA |
27 |
| 1978 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
69 |
| 1979 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
44 |
| 1980 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
49 |
| 1981 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
20 |
| 1982 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
France |
50 |
| 1983 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
USA |
74 |
| 1984 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Austria |
49 |
| 1985 |
Apheresis |
Allogeneic |
Post-PV Myelofibrose |
Hematology |
2024 |
Standard Therapy |
Germany |
59 |
| 1986 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
66 |
| 1987 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Poland |
58 |
| 1988 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
55 |
| 1989 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2024 |
Standard Therapy |
France |
70 |
| 1990 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
France |
54 |
| 1991 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
68 |
| 1992 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2024 |
Standard Therapy |
Poland |
41 |
| 1993 |
Apheresis |
Allogeneic |
Chronic Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
USA |
31 |
| 1994 |
Apheresis |
Allogeneic |
Other leukemia |
Hematology |
2024 |
Standard Therapy |
Italy |
31 |
| 1995 |
Apheresis |
Allogeneic |
Acute Myelogenous Leukemia |
Hematology |
2024 |
Standard Therapy |
Sweden |
42 |
| 1996 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
43 |
| 1997 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
52 |
| 1998 |
Apheresis |
Allogeneic |
Acute myeloid leukemia |
Hematology |
2024 |
Standard Therapy |
Germany |
64 |
| 1999 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
60 |
| 2000 |
Apheresis |
Autologous |
Multiple myeloma |
Hematology |
2024 |
Standard Therapy |
Germany |
70 |